Answers are grounded in this paper and cite their sources.
β-Thalassemia is a kind of single gene inheritance disease caused by HBB gene mutation. Traditional therapies, like lifelong blood transfusions and iron chelation, impose a heavy burden, while allogenic transplantation is limited by the lack of matched donors. Thus, there is an urgent need for curative ways free from donor availability. CRISPR-Cas9 gene editing offers two pathways: directly correcting the pathogenic HBB mutation by homology-directed repair (HDR) to restore adult hemoglobin (HbA), or disrupting the BCL11A erythroid enhancer through non-homologous end joining (NHEJ) to reactivate fetal hemoglobin (HbF) for functional compensation. This article compares these two strategies in five dimensions: molecular mechanisms, treatment process, clinical evidence, safety risks, and economic costs, and offers an assessment based on literature data and mechanistic analysis. Results show that the BCL11A enhancer editing strategy (exa-cel) has already approved for market use, offering broad applicability, contrary to direct HBB repair offering radical treatment limited by low HDR efficiency in hematopoietic stem cells and the risk of off-target effects involving homologous genes. The latter is mainly in preclinical stage. The article argues that it should put priority to establish the HbF-compensatory approach in short term, whereas long-term efforts should advance the radical treatment. Meanwhile, challenges arouse in balancing efficiency, safety, ethics and accessibility while developing gene editing.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: